49
total announcements
SUNPHARMA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 16 Oct 2026
Market Cap
₹4.23 L Cr
P/E (TTM)
35.0
P/E (Forward)
27.2
EPS (TTM)
₹50.40
52W Low
₹1,583.70
52W High
₹2,046.90
Dividend Yield
0.92%
Beta
0.14
Price / Book
5.1
Debt / Equity
5.5
Revenue (TTM)
₹59,911 Cr
Gross Margin
78.92%
Operating Margin
23.25%
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange about the schedule of its meet and earnings call for the first quarter ended 30 June 2026, which will be held on 31 July 2026. The company will announce its results on the same day.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has released an investor presentation highlighting its revenue composition, growth highlights, business operations, R&D and manufacturing capabilities, corporate governance, key financials, company history, and focus areas.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has published newspaper advertisements for its 34th Annual General Meeting and E-Voting, with copies attached as Annexure A available on the company's website.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has submitted a confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on stock exchanges.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of 34th Annual General Meeting to be held on 31 July 2026 along with the Annual Report for FY 2025-26.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has published a copy of a newspaper advertisement regarding the cancellation of a transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority and the notice of the 34th Annual General Meeting (AGM) along with the Annual Report for the financial year 2025-26.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
SUNPHARMA
Sun Pharmaceutical Industries Limited (SUNPHARMA) announced its agreement to acquire 100% of Innovcare Lifesciences Private Limited. Innovcare, a Mumbai-based company, is engaged in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products. This strategic acquisition is significant for investors as it expands Sun Pharma's product portfolio and market presence in these growing segments.